987 results on '"Ansell, Jack"'
Search Results
52. Disadvantages of VKA and requirements for novel anticoagulants
53. Thrombophilic Evaluation in Patients with Acute Pulmonary Embolism: Controversies and Evolving Concepts in Deep Venous Thrombosis and Pulmonary Embolism
54. Anticoagulation, Acute and Chronic: Indications and Methods
55. Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism
56. Indications for Inferior Vena Cava Filter Placement: Do Physicians Comply with Guidelines?
57. Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects
58. The Subtle Benefit of Anticoagulant Therapy for Splanchnic Vein Thrombosis
59. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial
60. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial
61. Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban
62. Target specific oral anticoagulants in the management of thromboembolic disease in the elderly
63. The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
64. Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
65. Heparins, Low-Molecular-Weight Heparins, and Pentasaccharides: Use in the Older Patient
66. Aripazine (PER977) reverses unfractionated and low molecular weight heparins, fondaparinux and new oral anticoagulants: report of a clinical trial with edoxaban and anticoagulant reversal biomarker identification.: 18.
67. “Reduce the Likelihood of Patient Harm Associated with the Use of Anticoagulant Therapy”: Commentary from the Anticoagulation Forum on the Updated Joint Commission NPSG.03.05.01 Elements of Performance
68. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM)
69. Quality of clinical documentation and anticoagulation control in patients with chronic nonvalvular atrial fibrillation in routine medical care
70. Contributors
71. Outpatient Anticoagulant Therapy
72. Management of venous thromboembolism: clinical guidance from the Anticoagulation Forum
73. The Impact of Patient Self-Testing of Prothrombin Time for Managing Anticoagulation: Rationale and Design of VA Cooperative Study #481—The Home INR Study (THINRS)
74. Extended Anticoagulation Therapy for the Primary and Secondary Prevention of Venous Thromboembolism
75. Patientsʼ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry
76. Current Options in the Prevention of Thromboembolic Disease
77. Reversal of Anticoagulation By Ciraparantag: Time to Onset and Duration of Effect
78. Point-of-care patient self-monitoring of oral vitamin K antagonist therapy
79. Approaches to the Prophylaxis and Treatment of Venous and Cardiac Thromboembolic Disease
80. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial
81. Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects.
82. Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation
83. Point-of-Care Testing in Oral Anticoagulant Monitoring: Implications for Patient Management
84. Long-Term Anticoagulation Therapy for Atrial Fibrillation in Elderly Patients: Efficacy, Risk, and Current Patterns of Use
85. Out-of-Hospital Coagulation Monitoring and Management
86. Oral rivaroxaban for acute DVT, or long term for VTE, is as effective as enoxaparin followed by a vitamin K antagonist for preventing recurrence, with no increase in bleeding complications
87. Correction to lepirudin dosage in table 1 of ‘Direct Thrombin Inhibitors’
88. Direct thrombin inhibitors
89. Apixaban versus Warfarin in Patients with Atrial Fibrillation
90. 37 - Outpatient Oral Anticoagulant Therapy
91. Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
92. Outpatient Anticoagulant Therapy
93. Contributors
94. Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: Findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry
95. Managing Vitamin K Antagonist Therapy: Patient Self-Management Or Traditional Care?: 45
96. Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale
97. Venous Thrombosis
98. CONTRIBUTORS
99. Anticoagulation Management as a Risk Factor for Adverse Events: Grounds for Improvement
100. Personalizing Health Care—Is This the Right Time for Warfarin?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.